Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial

Open access
Sharpe, Cynthia, Reiner, Gail E., Davis, Suzanne L., Nespeca, Mark, Gold, Jeffrey J., Rasmussen, Maynard, Kuperman, Rachel, Harbert, Mary Jo, Michelson, David, Joe, Priscilla, Wang, Sonya, Rismanchi, Neggy, Le, Ngoc Minh, Mower, Andrew, Kim, Jae, Battin, Malcolm R., Lane, Brian, Honold, Jose, Knodel, Ellen, Arnell, Kathy, Bridge, Renee, Lee, Lilly, Ernstrom, Karin, Raman, Rema, Haas, Richard H., FOR THE NEOLEV2 INVESTIGATORS · 2020 · Pediatrics

Abstract

BACKGROUND AND OBJECTIVES: There are no US Food and Drug Administration–approved therapies for neonatal seizures. Phenobarbital and phenytoin frequently fail to control seizures. There are concerns about the safety of seizure medications in the developing brain. Levetiracetam has proven efficacy and an excellent safety profile in older patients; therefore, there is great interest in its use in neonates. However, randomized studies have not been performed. Our objectives were to study the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment of neonatal seizures. METHODS: The study was a multicenter, randomized, blinded, controlled, phase IIb trial investigating the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment for neonatal seizures of any cause. The primary outcome measure was complete seizure freedom for 24 hours, assessed by independent review of the EEGs by 2 neurophysiologists. RESULTS: Eighty percent of patients (24 of 30) randomly assigned to phenobarbital remained seizure free for 24 hours, compared with 28% of patients (15 of 53) randomly assigned to levetiracetam (P < .001; relative risk 0.35 [95% confidence interval: 0.22–0.56]; modified intention-to-treat population). A 7.5% improvement in efficacy was achieved with a dose escalation of levetiracetam from 40 to 60 mg/kg. More adverse effects were seen in subjects randomly assigned to phenobarbital (not statistically significant). CONCLUSIONS: In this phase IIb study, phenobarbital was more effective than levetiracetam for the treatment of neonatal seizures. Higher rates of adverse effects were seen with phenobarbital treatment. Higher-dose studies of levetiracetam are warranted, and definitive studies with long-term outcome measures are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1542/peds.2019-3182

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Metadata

Authors
Sharpe, C., Reiner, G. E., Davis, S. L., Nespeca, M., Gold, J. J., Rasmussen, M., Kuperman, R., Harbert, M. J., Michelson, D., Joe, P., Wang, S., Rismanchi, N., Le, N. M., Mower, A., Kim, J., Battin, M. R., Lane, B., Honold, J., Knodel, E., Arnell, K., Bridge, R., Lee, L., Ernstrom, K., Raman, R., Haas, R. H., & FOR THE NEOLEV2 INVESTIGATORS
Venue
Pediatrics
Published
2020-06-01
Volume
145
Issue
6
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
OpenAlex
W3021808607
Cited by
207
References
1
FWCI
18.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.